Among HER2-postive BC patients treated with trastuzumab, 13.5% are forced to discontinue treatment due to associated cardiovascular events (30% due to heart failure and 70% due to asymptomatic LVEF decline). This evidence concerns the gene ERBB2 and breast cancer.